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Background: Delivery of Bacille Calmette-Guréin (BCG) Tokyo vaccine, with the multipuncture device, has been 
much preferred over BCG Pasteur, with the intradermal method, possibly due to the easier manner of 
administration, a desire to avoid any trouble with scars, as well as side effects and higher profits to providers 
in South Korea.
Methods: To determine BCG scar status in 0∼6 year old children vaccinated with two BCG vaccines (Pasteur BCG 
vaccine with intradermal method and BCG Tokyo vaccine with percutaneous method), the data from the national 
BCG scar survey in 2006 was analyzed.
Results: Based on the national survey, the high proportion that were vaccinated with BCG Tokyo vaccines with 
the multipuncture method (64.5%) was noted in 0∼6 year old Korean children. From inspection of scar formation, 
as an indicator of vaccination, the median number of the visible pin scars from the percutaneous method was 
16 (interquartile range, 12∼18) in the Korean children, and pin scars decreased as the age of the children increased 
(p＜0.001).
Conclusion: The findings in this survey clearly showed a growing preference of parents for the BCG Tokyo vaccines 
by the multipuncture method in South Korea.
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Introduction
  Although Bacille Calmette-Guréin (BCG) vaccine is 
the only currently available vaccine against tuberculosis, 
polices for BCG vaccination vary between countries. 
Many countries use the intradermal method of admin-
istration for BCG vaccination recommended by World 
Health Organization (WHO) and United Nations Child-
ren's Fund (UNICEF), while some countries such as 
Japan (and South Africa until 2002, South Korea, Brazil) 
use the percutaneous method of administration with a 
multipuncture technique. Brazil was the last country to 
use oral administration of BCG vaccine until this was 
discontinued in 1973. Other techniques such as scar-
ification, jet injection and use of bifurcated needles have 
been tried, but have yielded highly variable and in-
adequate results mainly because of inconsistent dose 
delivery, adverse reactions and low tuberculin con-
version rate1. In South Korea, the policy is to give BCG 
vaccination within the first month of birth along with 
revaccination given to some elementary children aged 
6 to 7 years if they have no visible BCG scar without 
prior tuberculin testing (until the revaccination policy 
was stopped in 2008). All the BCG vaccine needed in 
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the nation had been produced by the Korean Institute 
of Tuberculosis (KIT) until the year 2007. However as 
per Korea's liberalized import action since the 1990s, 
imported BCG vaccines, such as the BCG Tokyo vac-
cine given by multipuncture device, have been also in-
troduced to private health care providers. Use of the 
BCG Tokyo vaccine delivered by multipuncture device 
has been constantly increasing because it is known to 
be less scarring and to have lower rates of side effects 
compared to the BCG Pasteur vaccine given by the in-
tradermal method2,3. Also, the private sector prefers to 
use the imported vaccines not only due to the higher 
profits, but also due to the easier means of admin-
istration which does not require special training.
  Percutaneous administration methods are simpler 
with a low rate of adverse reactions but are less con-
sistent in terms of delivery dose4. Intradermal injection 
using a syringe and needle is generally accepted as the 
most accurate method, because the delivered dose can 
be precisely measured and controlled, resulting in more 
consistent mycobacteria-specific immunity5,6. The down-
side of using the intradermal method is a higher rate 
of local reactions such as ulcers and lymphadenitis than 
other methods when other vaccine specific factors are 
controlled5. The implications of intradermal versus per-
cutaneous administration routes have long been de-
bated but, the relative protective efficacy of the two is 
not yet known. However, there have been some studies 
that compared the effect of vaccine route on T cell im-
munity against tuberculosis. Kemp et al.6 demonstrated 
that Mycobacterium tuberculosis-specific interferon-γ 
(IFN-γ) production was increased after the intradermal 
route of BCG vaccination but not by the percutaneous 
route in healthy volunteers. Also, Hussey et al.7 in 
South Africa demonstrated that there was a trend for 
greater IFN-γ responsiveness following the intradermal 
route of vaccination compared with percutaneouly ad-
ministered BCG vaccine. On the other hand, in contrast 
with those of Kemp et al.6, a recent study in South 
Africa found that percutaneous vaccination with 
Japanese BCG induced significantly greater helper T cell 
(Th)-1 cytokines in whole blood of neonates than did 
intradermal vaccination with Danish BCG8. These stud-
ies with different conclusions suggest that the vaccine 
route can affect M. tuberculosis-specific T cell immunity 
in terms of IFN-γ and other T cell-derived cytokines, 
but it might be important to determine its actual effect 
on the variable vaccine efficacy and clinical con-
sequences of vaccination in particular populations.
  Therefore, it is necessary to investigate the current 
status of BCG vaccination in young children who have 
been affected by the diversity of BCG vaccines in use 
in the public and private sector in South Korea. Using 
the data from this BCG scar survey, we can evaluate 
whether proper BCG vaccination delivered by the two 
different administration methods has been performed in 
the nation. Findings from this study will provide base-
line data to health policy decision makers to assist in 
evaluating the performance of the existing BCG vacci-
nation program and to provide a better understanding 
of the BCG vaccines recently used in South Korea.
Materials and Methods
1. Study population
  During 2006, as part of the National Tuberculosis 
(TB) Control Program of the Korea Center for Disease 
Control and Prevention (KCDCP) and the KIT, a BCG 
scar survey was carried out with technical assistance 
from the regional public health care centers and the 
KIT. Those children aged 0∼6 years old were recruited 
from day-care centers and kindergartens, randomly se-
lected by one-stage cluster sampling from every 16 cities 
and provinces of South Korea. Selected day-care centers 
or kindergartens which refused to participate were ex-
cluded, and a total of 121 institutions took part in the 
survey in the end.
  This study was ethically approved by the Institutional 
Review Board of the International Vaccine Institute, 
Seoul (protocol # 2006-006). The parents or guardians 
of all subjects gave a written consent form for their chil-
dren to participate.
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2. BCG scar survey
  Prior to inspection of BCG scar formation, a letter 
containing a written consent form and questionnaire 
asking about history of BCG vaccination, type of BCG 
vaccines, and family history of TB was distributed to pa-
rents/guardians of all subjects.
  The health care workers inspected BCG scars by ex-
amining the left and right upper arms or elsewhere, by 
measuring BCG scar diameter (BCG Pasteur) and count-
ing the number of puncture scars (BCG Tokyo). The 
BCG scar was recorded as 'intradermal method', 'multi-
puncture method' or 'no scar.' The presence of a BCG 
scar(s) was accepted as evidence of previous BCG vac-
cination regardless of the presence of parental report of 
BCG vaccine.
3. Statistical analysis
  Data was analyzed using Stata software version 11.0 
(Stata Corp., College Station, TX, USA). Comparisons 
were made between groups to test for statistical evi-
dence of differences. Chi squared tests were used to 
compare different groups according to which vaccine 
they received. In addition, the non-parametric analysis, 
Kruskal-Wallis test and Wilcoxon rank sum test, was 
used to compare the scar size and pin scar numbers 
in different age groups.
Results
1. Characteristics of participants by the type of BCGs
  For the investigation of BCG scar formation, the data 
from a total of 5,713 children were used, collected from 
121 day-care centers and kindergartens in 16 cities of 
South Korea. From the information collected for those 
children whose parents responded to the questionnaire, 
there were 2,995 male and 2,718 female children with 
a ratio 1.1 to 1. Among the 5,713, for 95.6% (n=5,462) 
the parent indicated that the child had been vaccinated 
with BCG.
  The distribution of BCG scar status in the Table 1 was 
categorized primarily by the data collected from scar in-
spection in the field. When an examiner recorded the 
child as 'no BCG scar' during the inspection but the pa-
rents had ticked vaccination with one of BCGs in the 
questionnaire, the answer from the parents was used. 
However, when an examiner recorded the child as 'no 
BCG scar' during the inspection and the parents marked 
'not sure' for BCG status in the survey, then this was 
categorized as 'no scar' in the analysis.
  For those children who had been inspected for BCG 
scar, 1,778 (31.1%) had been vaccinated with BCG 
Pasteur by the intradermal method and 3,684 (64.5%) 
with BCG Tokyo by the multipuncture method. From 
this analysis, 251 children (4.4%) had 'no BCG scar' 
with an increasing trend by age. 
  Among girls, 31.6% had been vaccinated with BCG 
Pasteur by the intradermal method (n=817) and 68.4% 
with the BCG Tokyo by the multipuncture method 
(n=1,769). Among boys, 15.9% had been vaccinated 
with BCG Pasteur by the intradermal method (n=361) 
and 84.1% with the BCG Tokyo by the multipuncture 
method (n=1,915).
  The distribution of the type of BCGs varied by age, 
showing the proportions of BCG given with the intra-
dermal method were from 45.3% to 23.7% (p＜0.0001). 
It is noted that children less than 2 years old had rela-
tively higher proportions of BCG Pasteur with the intra-
dermal method than had been expected. Looking sepa-
rately at the data collected from day-care centers and 
kindergartens, the proportion of BCG Pasteur vacci-
nation with the intradermal method increased by age, 
indicating that the proportion of children vaccinated 
with BCG Tokyo with the multipuncture method was 
gradually increasing in recent years.
  Analysis of the providers of BCG vaccination, in the 
case of children given BCG Pasteur/intradermal, 88.7% 
of responders said that their children had been vacci-
nated in public health care centers. On the other hand, 
the data showed that private clinics preferred to provide 
BCG Tokyo/multipuncture.
  Interestingly, 7.4% of parents/guardians of BCG 
Tokyo vaccinees responded in the survey that their chil-
dren had received the vaccine in public health care cen-
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Table 1. Characteristics of participants by the type of BCG vaccination
Characteristics
BCG scar
Total (%)
Intradermal (%) Multipuncture (%) No scar (%)*
Age, yr ＜1  139 (42.9)  185 (57.1)   0 (0)  324 (5.67)
1  154 (45.3)  185 (54.4)   1 (0.3)  340 (5.95)
2   87 (30.6)  191 (67.3)   6 (2.1)  284 (4.97)
3  137 (23.7)  427 (74.0)  13 (2.3)  577 (10.10)
4  276 (24.7)  792 (70.8)  50 (4.5) 1,118 (19.57)
5  498 (28.8) 1,128 (65.2) 105 (6.1) 1,731 (30.30)
6  487 (36.4)  776 (58.0)  76 (5.7) 1,339 (23.44)
Vaccine provider Obstetrics/Gynecology Clinic  128 (14.4)  725 (81.6)  36 (4.1)  889 (15.56)
Pediatrics  289 (11.9) 2,036 (83.5) 114 (4.7) 2,439 (42.69)
Internal Medicine    5 (12.8)   29 (74.4)   5 (12.8)   39 (0.68)
General hospital  140 (15.5)  734 (81.5)  27 (3.0)  901 (15.77)
Public Health Center 1,179 (88.7)   98 (7.4)  52 (3.9) 1,329 (23.26)
Other    5 (18.5)   19 (70.4)   3 (11.1)   27 (0.47)
Not reported  186 (39.1)  275 (57.8)  15 (3.2)  476 (8.33)
Insurance payment†, KW ＜20,000   91 (37.1)  136 (55.5)  18 (7.4)  245 (4.29)
20,000∼50,000  583 (36.0)  972 (59.9)  69 (4.3) 1,624 (28.43)
50,000∼100,000  656 (28.0) 1,589 (67.7) 104 (4.4) 2,349 (41.12)
100,000∼150,000  166 (27.0)  420 (68.2)  30 (4.9)  616 (10.78)
150,000∼200,000   62 (29.8)  143 (68.8)   3 (1.4)  208 (3.64)
＞200,000   34 (17.4)  149 (76.4)  12 (6.2)  195 (3.41)
Areas Seoul  196 (26.7)  519 (70.7)  19 (2.6)  734 (12.85)
Busan  102 (19.5)  395 (75.5)  26 (4.97)  523 (9.15)
Incheon   62 (23.2)  175 (65.5)  30 (11.2)  267 (4.67)
Daegu   96 (25.4)  266 (70.4)  16 (4.2)  378 (6.62)
Gwangju  139 (41.5)  189 (56.4)   7 (2.1)  335 (5.86)
Ulsan   54 (14.1)  283 (73.9)  46 (12.0)  383 (6.70)
Gyeonggi  196 (24.8)  553 (70.1)  40 (5.1)  789 (13.81)
Gangwon   75 (46.3)   87 (53.7)   0 (0)  162 (2.84)
Chungcheongbuk  336 (54.1)  275 (44.3)  10 (1.6)  621 (10.87)
Chungcheongnam  124 (33.5)  221 (59.7)  25 (6.8)  370 (6.48)
Kyungsangbuk   69 (26.1)  194 (73.5)   1 (0.4)  264 (4.62)
Kyungsangnam  104 (21.5)  362 (74.8)  18 (3.7)  484 (8.47)
Jeonrabuk   89 (53.3)   72 (43.1)   6 (3.6)  167 (2.92)
Jeonranam  123 (56.9)   86 (39.8)   7 (3.2)  216 (3.78)
Jeju   13 (65.0)    7 (35.0)   0 (0)   20 (0.35)
Total 1,778 3,684 251 5,713
*This included 'no BCG scar' during inspection, and the parent marked 'not sure' in the questionnaire of the survey. †Data on
insurance payment used as a proxy for household income in South Korea. 
BCG: Bacille Calmette-Guréin.
ters, where the BCG Tokyo vaccine is not provided. 
This may be due to recall bias or inaccuracy in record-
ing, given that in the private sector vaccination is also 
provided from a public health center. Compared to the 
other private clinics, pediatrics clinics had a significantly 
lower proportion of vaccination with BCG Pasteur/intra-
dermal as 11.9%.
  To observe any association with the economic status 
of parents/guardians, information on monthly insurance 
payments in proportion to their incomes was collected 
in the survey. The data showed that those parents/ 
guardians who paid the higher insurance payments 
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Table 2. Distribution of BCG scars by age among BCG recipients
Age
Scar size (mm) in BCG Pasteur recipients Pin scar numbers in BCG Tokyo recipients 
No. Median Lower quartile
Upper 
quartile IQR No. Median
Lower 
quartile
Upper 
quartile IQR
＜1 139 5 4 7 3 185 18 15 18 3
1 154 6 5 8 3 185 18 14 18 4
2 87 5 4 6 2 191 18 16 18 2
3 137 5 3 6 3 427 17 13 18 5
4 276 5 4 6 2 792 16 12 18 6
5 498 4 3 5 2 1,128 16 11 18 7
6 487 5 4 6 2 776 16 11 18 7
Total 1,778 5 4 6 2 3,684 16 12 18 6
BCG: Bacille Calmette-Guréin; No.: number of subjects; IQR: interquartile range.
Figure 1. Distribution of scar size (mm) among BCG 
Pasteur recipients by age. The figure excludes data from
children with no scar. The different lines indicate each age
group from 0 year to 6 years old. BCG: Bacille Calmette-
Guréin.
(which indicates higher incomes) had the higher pro-
portion of vaccination with BCG Tokyo/multipuncture 
(p＜0.0001).
  In terms of the regional preference of the type of 
BCGs, 35.0% of children living in Jeju had been vacci-
nated with BCG Tokyo/multipuncture while 75.5% of 
children living in Busan had been vaccinated with the 
same vaccination, showing that the big cities with high-
er income had a relatively high proportion of BCG 
Tokyo/multipuncture than other smaller cities. Since 
BCG Tokyo/multipuncture is more expensive than BCG 
Pasteur/intradermal which is free of charge, it seems 
children in bigger cities had more access to the more 
expensive BCG Tokyo vaccine.
2. BCG scar formation
  Among those children who had been vaccinated with 
BCG Pasteur by the intradermal method at the age of 
0 to 6 years (n=1,778), the overall median of the BCG 
scar size was 5.0 mm (interquartile range [IQR], 1∼15). 
According to the non-parametric analysis in Table 2, the 
data shows that the medians of scar size were sig-
nificantly different by age (Kruskal-Wallis test, p＜ 
0.001), especially the older age group (4∼6 years) had 
significantly higher scar sizes than the younger age 
group (0∼3 years) (Wilcoxon rank sum test, p＜ 
0.001). There were 75 children (4.2%) who had scar 
sizes of more than 10 mm, which needs further inves-
tigation as to whether this was due to keloid formation 
or recording errors. From observation of the distribution 
in scar size, it is noted that there are distinct peaks at 
5 and 10 mm (Figure 1). It might be possible that exam-
iners from public health care centers had 'digital prefer-
ences' when measuring the size of BCG scar at the 
inspection. 
  Among those children who had been vaccinated with 
BCG Tokyo/multipuncture, the number of BCG pin 
scars was recorded at ages of 0 to 6 years from the scar 
survey (n=3,684). For all the children, the median of 
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pin scars was 16 (IQR, 12∼16), the maximum number 
of pin scars was 36, and the minimum number was 1. 
According to the non-parametric analysis in Table 2, the 
data shows that the medians of pin scar number were 
significantly different by age (Kruskal-Wallis test, p＜ 
0.001), especially the younger age group (0∼3 years) 
had significantly higher pin scars than the older age 
group (4∼6 years) (Wilcoxon rank sum test, p＜ 
0.001).
Discussion
  From this scar survey, 4.4% of responders had no 
BCG scar. Based on the national tuberculosis survey in 
1995, the rate of BCG vaccination under 10 years old 
was 87.7%9. Comparing these data, it seems the rate of 
BCG vaccination has improved since 1995. However, 
the reporting rate of BCG vaccination has been slightly 
decreasing, taking into consideration the figures of 
80.3% in 2002, 77.8% in 2003, and 77.7% in 2004. A 
lot of individuals on whom data were collected may not 
have been properly reported to the surveillance pro-
gram, which has no system of collecting data from all 
the private clinics. This suggests that the current report-
ing system should be examined and improved so as to 
include information on all vaccinated children.
  From the data for the age of 0 to 6 years, 64.5% of 
responders had been vaccinated with BCG Tokyo/multi-
puncture. It appears that only 11.8% of responders in 
pediatric clinics and 14.4% of responders in obstetrics/ 
gynecology clinics, had vaccination with BCG Pasteur/ 
intradermal, showing that most of the private clinics 
prefer to use the BCG Tokyo vaccine. It seems the use 
of BCG Tokyo by the multipuncture method in private 
sector has been gradually increasing compared to that 
of BCG Pasteur given by the intradermal method. In ad-
dition to an easier manner of administration, less scar-
ring and higher profits to the providers, the private sec-
tor may also favor using the BCG Tokyo strain, consid-
ering the fact that BCG Tokyo strain is known to be 
one of the 'weak' BCG strains with lower frequencies 
of side effects such as BCG lymphadenitis than 'strong' 
strains such as BCG Pasteur and BCG Danish10,11.
  As the multipuncture method uses a device with 9 
needles twice, a maximum of eighteen BCG scars 
should remain in the skin when properly injected, but 
previous studies have found that typically only 9 to 11 
BCG scars remained a few years after vaccination12,13. 
In this survey, the data showed that the median of pin 
number scars was 16 (IQR, 12∼18) among 3,684 BCG 
Tokyo recipients at the age of 0∼6 years. In children 
less than 12 months old, the median of pin number was 
18 (IQR, 15∼18), while the median of pin number in 
6 years old was 16 (IQR, 11∼18), showing a decreasing 
trend of pin scars over time. This may provide further 
evidence of the disappearance of pin scars over time, 
although we cannot discount the possibility that as the 
use of BCG delivered with the multipuncture device in-
creased over time, the injection technique improved, 
which may have resulted in increased numbers of pin 
scars in younger children.
  The findings in the survey clearly showed a growing 
preference of parents for the BCG Tokyo vaccine by the 
multipuncture method in South Korea. This suggests 
that special training and education to ensure accurate 
injection in the private sector will have to be planned 
by the government.
Acknowledgements
  This project was financially supported by the Interna-
tional Tuberculosis Research Center, Masan, Korea.
References
1. Tan JS, Canaday DH, Boom WH, Balaji KN, Schwander 
SK, Rich EA. Human alveolar T lymphocyte responses 
to Mycobacterium tuberculosis antigens: role for CD4＋ 
and CD8＋ cytotoxic T cells and relative resistance of 
alveolar macrophages to lysis. J Immunol 1997;159: 
290-7.
2. Kim HJ, Oh SY, Lee JB, Park YS, Lew WJ. Tuberculin 
survey to estimate the prevalence of tuberculosis in-
fection of the elementary schoolchildren under high 
BCG vaccination coverage. Tuberc Respir Dis 2008;65: 
269-76.
H Lee et al: BCG scar survey in South Korea
380
3. Kim HJ, Oh SY, Lee JB. Report on Comparison of Each 
Strain (Pasteur, Danish, Tokyo) of BCG Efficacy Using 
Tuberculin Test and Adverse Reactions. Seoul: Korean 
Institute of Tuberculosis; 2008.
4. Fine PE, Carneiro IA, Milstien JB, Clements CJ. Issues 
relating to the use of BCG immunization programmes. 
Report No. WHO/V&B/99.23. Geneva: World Health 
Organization; 1999.
5. Gheorghiu M. The present and future role of BCG vac-
cine in tuberculosis control. Biologicals 1990;18:135- 
41.
6. Kemp EB, Belshe RB, Hoft DF. Immune responses 
stimulated by percutaneous and intradermal bacille 
Calmette-Guerin. J Infect Dis 1996;174:113-9.
7. Hussey GD, Watkins ML, Goddard EA, Gottschalk S, 
Hughes EJ, Iloni K, et al. Neonatal mycobacterial spe-
cific cytotoxic T-lymphocyte and cytokine profiles in 
response to distinct BCG vaccination strategies. Immu-
nology 2002;105:314-24.
8. Davids V, Hanekom WA, Mansoor N, Gamieldien H, 
Gelderbloem SJ, Hawkridge A, et al. The effect of ba-
cille Calmette-Guérin vaccine strain and route of ad-
ministration on induced immune responses in vacci-
nated infants. J Infect Dis 2006;193:531-6.
9. Korea Centers for Disease Control and Prevention, 
Korean National Tuberculosis Association. Report on 
the 7th Tuberculosis Prevalence Survey in Korea, 1995. 
Seoul: Korea Centers for Disease Control and Preven-
tion, Korean National Tuberculosis Association; 1996.
10. Gheorghiu M, Lagrange PH. Viability, heat stability and 
immunogenicity of four BCG vaccines prepared from 
four different BCG strains. Ann Immunol (Paris) 1983; 
134C:125-47.
11. Lagranderie MR, Balazuc AM, Deriaud E, Leclerc CD, 
Gheorghiu M. Comparison of immune responses of 
mice immunized with five different Mycobacterium bo-
vis BCG vaccine strains. Infect Immun 1996;64:1-9.
12. Nakatani H, Fujii N, Mori T, Hoshinot H. Epidemio-
logical transition of tuberculosis and future agenda of 
control in Japan: results of the Ad-Hoc National Survey 
of Tuberculosis 2000. Int J Tuberc Lung Dis 2002;6: 
198-207.
13. Sugishita Y, Maeda H, Mori T. Variation in yield of nee-
dle scars with multipuncture BCG vaccination. Nihon 
Koshu Eisei Zasshi 2005;52:1045-9.
